Piramal Pharma

Piramal Enterprises Limited operates in financial services and pharmaceuticals businesses in India, North America, Europe, Japan, and internationally. It operates through Pharmaceuticals Manufacturing and Services, and Financial Services segments. The company provides housing finance and other financing solutions, such as private equity, structured debt, senior secured debt, construction finance, and flexi lease rental discounting to real estate sector; and funding solutions to infrastructure, renewable energy, roads, industrials, auto components, and other sectors. It also operates distressed asset investing platform that invests in equity and/or debt in assets. In addition, the company offers contract development and manufacturing solutions, including drug discovery, production, and manufacturing of active pharmaceutical ingredients and formulations; and inhalation and injectable anaesthesia, injectable pain, antibiotics, and other medications, as well as intrathecal spasticity management drugs. Further, it provides over-the-counter products comprising analgesics, skin care, kids' wellness, digestives, women's health, disinfectant, Covifind, and hygiene and protection products, as well as vitamins, minerals, and supplements primarily under the Saridon, Lacto Calamine, Little's, I-Pill, Supradyn, Polycrol, Triactiv, Ourdaily, Pulse Oximeters, and Tetmosol brands. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited was incorporated in 1947 and is based in Mumbai, India.

In the early 1980s, Ajay Piramal took over the reins of Piramal Group. In 1984, the group acquired Gujarat Glass Limited, a manufacturer of glass packaging for pharmaceutical and cosmetic products, followed by Ceylon Glass in 1999.In 1988, the group bought Nicholas Laboratories, which later flourished and by 2010 reached the highest valuation in the pharmaceutical industry. Over the decade, the company acquired many business units to strengthen their presence.

In 1999, Piramal Glass acquired Ceylon Company Limited, Sri Lanka.In 2006, the company bought Pfizer’s UK manufacturing facility in Morpeth. The company also formed the Piramal Foundation, a philanthropic arm of the group.

In 2007, it underwent a deal with Merck Pharmaceuticals for development and discovery of new drugs.

In 2008, it signed a second drug development deal with Eli Lilly and Company.

The company Nicholas Laboratories was renamed to Piramal Healthcare Ltd.

In 2010, Piramal Healthcare sold its domestic formulations business to Abbott for $3.72 billion . It was considered to the "most expensive pharma deal ever" by Forbes India. Piramal Healthcare then sold its diagnostics chain Piramal Diagnostic Services to SRL for ?600 crore. In the same year, the group formed its own real estate entity, Piramal Realty.2011 saw Fortune 500 ranking Piramal Healthcare in the top-50 largest corporations across India. UN Conference on Trade and Development’s World Investment Report 2011 ranked Piramal Healthcare as No. 5 in the top 10 pharmaceutical contract manufacturers worldwide. In 2011–12, Piramal bought 11% in Vodafone Essar. In 2014, it sold its 11% Stake in Vodafone India to Prime Metals, an indirect subsidiary of Vodafone Group. In 2012, Piramal Healthcare was renamed to Piramal Enterprises Ltd.

BST-CarGel, Piramal's innovative bio-orthopaedic product for cartilage repair, received European CE mark approval.

Piramal's Decision Resources Group acquired Abacus International, a UK based company.

Piramal Enterprises acquired the brand Caladryl in India. Caladryl is an anti-pruritic solution known for dermatosis application for minor skin irritations and itching. This acquisition enabled Piramal Enterprises to widen its consumer products portfolio in the skin care segment.Piramal Imaging entered into a Strategic Partnership and Exclusive Licensing Agreement with Ci-Co Healthcare for Commercialization of florbetaben F18.European Union’s CHMP recommends EU approval of Piramal Imaging’s radiopharmaceutical NeuraCeq .In December 2020, Piramal Glass was sold to The Blackstone Group for US$1 billion.

The philosophy of 'Doing Well and Doing Good', along with our core values of Knowledge, Action, Care & Impact have been constant in our journey and serve as guideposts to help us become the company we would like to be.

Our purpose provides clear guidance to our people and ensures that we identify the right partners to create mutual, enduring value.

In 2007, it underwent a deal with Merck Pharmaceuticals for development and discovery of new drugs.

In 2008, it signed a second drug development deal with Eli Lilly and Company.

The company Nicholas Laboratories was renamed to Piramal Healthcare Ltd.

BST-CarGel, Piramal's innovative bio-orthopaedic product for cartilage repair, received European CE mark approval.

Piramal's Decision Resources Group acquired Abacus International, a UK based company.

Our purpose provides clear guidance to our people and ensures that we identify the right partners to create mutual, enduring value.

Piramal Pharma

Share

Contacts

Follow Us

Piramal Pharma

Share

Contacts

Follow Us